196 related articles for article (PubMed ID: 19630105)
1. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease.
Lakatos PL; Czegledi Z; Szamosi T; Banai J; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp J; Lakatos L
World J Gastroenterol; 2009 Jul; 15(28):3504-10. PubMed ID: 19630105
[TBL] [Abstract][Full Text] [Related]
2. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.
Szamosi T; Banai J; Lakatos L; Czegledi Z; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp M; Papp J; Lakatos PL
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):872-9. PubMed ID: 19648821
[TBL] [Abstract][Full Text] [Related]
3. Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression.
Magro F; Rodrigues-Pinto E; Coelho R; Andrade P; Santos-Antunes J; Lopes S; Camila-Dias C; Macedo G
Am J Gastroenterol; 2014 Jul; 109(7):1026-36. PubMed ID: 24796767
[TBL] [Abstract][Full Text] [Related]
4. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009.
Lakatos PL; Golovics PA; David G; Pandur T; Erdelyi Z; Horvath A; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Veres G; Lovasz BD; Szathmari M; Kiss LS; Lakatos L
Am J Gastroenterol; 2012 Apr; 107(4):579-88. PubMed ID: 22233693
[TBL] [Abstract][Full Text] [Related]
5. Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease.
Qiu Y; Chen BL; Feng R; Zhang SH; He Y; Zeng ZR; Ben-Horin S; Peyrin-Biroulet L; Mao R; Chen MH
J Gastroenterol Hepatol; 2018 Mar; 33(3):664-670. PubMed ID: 28940780
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine.
Lecomte T; Contou JF; Beaugerie L; Carbonnel F; Cattan S; Gendre JP; Cosnes J
Dis Colon Rectum; 2003 Nov; 46(11):1469-75. PubMed ID: 14605564
[TBL] [Abstract][Full Text] [Related]
7. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
Chebli JM; Gaburri PD; De Souza AF; Pinto AL; Chebli LA; Felga GE; Forn CG; Pimentel CF
J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?
Kiss LS; Papp M; Lovasz BD; Vegh Z; Golovics PA; Janka E; Varga E; Szathmari M; Lakatos PL
Inflamm Bowel Dis; 2012 Sep; 18(9):1647-54. PubMed ID: 22081542
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience.
Suárez Ferrer C; González-Lama Y; González-Partida I; Calvo Moya M; Vera Mendoza I; Matallana Royo V; Arevalo Serrano J; Abreu Garcia L
Dig Dis Sci; 2019 Mar; 64(3):875-879. PubMed ID: 30542812
[TBL] [Abstract][Full Text] [Related]
10. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort.
Lovasz BD; Lakatos L; Horvath A; Szita I; Pandur T; Mandel M; Vegh Z; Golovics PA; Mester G; Balogh M; Molnar C; Komaromi E; Kiss LS; Lakatos PL
World J Gastroenterol; 2013; 19(14):2217-26. PubMed ID: 23599648
[TBL] [Abstract][Full Text] [Related]
11. Smoking status and response to thiopurines in steroid-dependent inflammatory bowel disease.
Domènech E; Carrión S; Garcia-Planella E; Mañosa M; Gordillo J; Concepción M; Guarner C; Cabré E
Inflamm Bowel Dis; 2011 Apr; 17(4):971-5. PubMed ID: 20824819
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy with thiopurines in stricturing Crohn's disease: A real-life experience from low- and middle-income countries.
Kante B; Vuyyuru SK; Kedia S; Sahu P; Kumar P; Ranjan MK; Virmani S; Sharma R; Madhusudhan KS; Panwar R; Das P; Makharia G; Ahuja V
Indian J Gastroenterol; 2022 Aug; 41(4):343-351. PubMed ID: 35997952
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and predictors of clinical outcomes in Korean patients with Crohn's disease: a Korean association for the study of intestinal diseases multicenter study.
Moon CM; Park DI; Kim ER; Kim YH; Lee CK; Lee SH; Kim JH; Huh KC; Jung SA; Yoon SM; Song HJ; Jang HJ; Kim YS; Lee KM; Shin JE
J Gastroenterol Hepatol; 2014 Jan; 29(1):74-82. PubMed ID: 23981141
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children.
Jeshion WC; Larsen KL; Jawad AF; Piccoli DA; Verma R; Maller ES; Baldassano RN
J Clin Gastroenterol; 2000 Apr; 30(3):294-8. PubMed ID: 10777191
[TBL] [Abstract][Full Text] [Related]
15. Impact of timing and duration of thiopurine treatment on first perianal surgery in Crohn's disease: UK population-based study (1995-2009).
Chhaya V; Saxena S; Cecil E; Subramanian V; Curcin V; Majeed A; Pollok RC
Inflamm Bowel Dis; 2015 Feb; 21(2):385-91. PubMed ID: 25569740
[TBL] [Abstract][Full Text] [Related]
16. Clinical course in Crohn's disease: factors associated with behaviour change and surgery.
Arieira C; Cúrdia Gonçaves T; Dias de Castro F; João Moreira M; Cotter J
Scand J Gastroenterol; 2018; 53(10-11):1222-1227. PubMed ID: 30345845
[TBL] [Abstract][Full Text] [Related]
17. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
Miehsler W; Reinisch W; Moser G; Gangl A; Vogelsang H
Am J Gastroenterol; 2001 Mar; 96(3):782-7. PubMed ID: 11280551
[TBL] [Abstract][Full Text] [Related]
18. A risk score system to timely manage treatment in Crohn's disease: a cohort study.
Pallotta N; Vincoli G; Pezzotti P; Giovannone M; Gigliozzi A; Badiali D; Vernia P; Corazziari ES
BMC Gastroenterol; 2018 Nov; 18(1):164. PubMed ID: 30400823
[TBL] [Abstract][Full Text] [Related]
19. Tolerance and efficacy of azathioprine in pediatric Crohn's disease.
Riello L; Talbotec C; Garnier-Lengliné H; Pigneur B; Svahn J; Canioni D; Goulet O; Schmitz J; Ruemmele FM
Inflamm Bowel Dis; 2011 Oct; 17(10):2138-43. PubMed ID: 21910176
[TBL] [Abstract][Full Text] [Related]
20. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
Mantzaris GJ; Christidou A; Sfakianakis M; Roussos A; Koilakou S; Petraki K; Polyzou P
Inflamm Bowel Dis; 2009 Mar; 15(3):375-82. PubMed ID: 19009634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
